HCV-IN-4

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].

FC1=C2C=3N([C@@H](OC2=CC(=C1)C=4NC(=NC4)[C@H]5N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC5)C=6C=C7C(=CC6)CCCO7)C=8C(C3)=CC(=CC8)C=9NC(=NC9)[C@H]%10N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC%10